Full-Time

Senior Category Manager Primary Packaging

Posted on 5/12/2026

Deadline 5/25/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Bridgewater Township, NJ, USA + 1 more

More locations: Jacksonville, FL, USA

In Person

Requires 10-15% travel (domestic/international); on-site at Raritan, NJ; Jacksonville, FL; or Zug, Switzerland.

Category
Operations & Logistics (1)
Required Skills
Risk Management
Requirements
  • Bachelor’s degree
  • 7-10 Years of related experience
  • Strategic Leadership – ability to set vision and direction for category managers.
  • Talent Development – proven experience in building high-performing teams.
  • Business Acumen – strong financial, operational, and supply chain expertise.
  • Stakeholder Engagement – ability to partner and influence across R&D, Ops, and commercial functions.
  • Supplier Executive Management – experience managing global supplier partnerships.
  • Innovation & Sustainability Advocacy – drive towards next-gen, eco-friendly packaging.
  • Supplier Relationship Management & Negotiation Skills
  • Customer-Centricity & Stakeholder Focus – ability to view business units as customers, anticipate needs, and tailor category strategies to enable business success
  • Strong Communication and Executive Presence
  • Ability to travel 10-15% (Domestic/International)
  • Preferred Minimum Education: Masters in Engineering, Material Science, Packaging Science, Supply Chain Management
  • Preferred Knowledge, Skills and Abilities: APICS / ISM/ CPSM Certification
  • Preferred Related Industry Experience: Prior Category Management experience in Packaging
  • Familiarity with regional and global regulatory and quality standards in healthcare packaging (ISO, FDA, MDR, UDI, serialization, PPWR etc.)
Responsibilities
  • Lead the Primary Packaging Category and Supplier Relationship Management Team to develop E2E business category strategy and execution, supplier management and risk mitigation across Surgery, EPNV, Vision business units in MedTech.
  • Reporting into the MedTech Center Category Management Leader, provide overall coordination, facilitation and enablement of programs that will drive best practices and leverage across J&J Enterprise.
  • Set clear goals, priorities, and performance measures to ensure alignment with business objectives while fostering a culture of collaboration, accountability, and innovation within the team.
  • Responsible for providing a practical and intellectual understanding of the global MedTech industry and its channels in order to provide a strong combination of strategic vision and hands-on leadership in all aspects of global sourcing operations.
  • Provide oversight and direction for global packaging category strategies.
  • Ensure alignment across sub-categories and business units to capture synergies and scale benefits.
  • Drive portfolio-level decisions (make/buy, supplier footprint, risk diversification, sustainability, simplification & rationalization).
  • Oversee category pipeline execution to deliver cost savings, resilience, and innovation.
  • Be responsible for managing all aspects of the relationship within Packaging Material suppliers to deliver reliable product supply and total cost reduction.
  • Develop a supplier strategy that segments suppliers, assesses and governs performance, rationalizes the supply base, and drives continuous improvement.
  • Monitor supplier contract maintenance and negotiations, ensuring alignment with current business requirements.
  • Guide the team in supplier segmentation and relationship management, ensuring strategic partnerships and performance excellence.
  • Act as executive sponsor for key supplier relationships, enabling innovation and executive-level engagement.
  • Monitor global packaging market trends, cost drivers, and index-based pricing models to inform sourcing strategies.
  • Monitoring and benchmark existing supply base within the global marketplace.
  • Foster a customer-first culture within the team, positioning procurement as a trusted advisor and value-adding partner.
  • Represent Packaging Procurement with senior stakeholders in R&D, Operations, Regulatory, and Quality.
  • Partner with Design and Sustainability teams to drive next-generation packaging solutions.
  • Ensure the team supports regulatory compliance (FDA, MDR, UDI, serialization) and patient safety standards.
  • Work with internal and external stakeholders to develop and deploy local strategies that align with Category objectives andthat impact cost, quality, service, SEI, Supplier Diversity, SRM and supplier consolidation activities and metrics.
  • Deliver on financial targets including savings, cost avoidance, cash flow and value creation (short, mid and long term).
  • Establish and track KPIs across quality, service, risk, sustainability, and innovation.
  • Support enterprise-wide initiatives such as digital procurement, PPWR, supplier diversity, and ESG commitments.
Desired Qualifications
  • Masters in Engineering, Material Science, Packaging Science, Supply Chain Management
  • Prior Category Management experience in Packaging
  • Working knowledge and experience in Sourcing Processes, Contracting, Negotiations
  • Strong knowledge of packaging materials, technologies, and supply markets, ideally within medical devices, pharma, life sciences or FMCG
  • Familiarity with regional and global regulatory and quality standards in healthcare packaging (ISO, FDA, MDR, UDI, serialization, PPWR etc.)
  • APICS / ISM/ CPSM Certification

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.